Evogene reported Q2 2024 revenue of $605.0K, missed analyst consensus of $800.0K by $195.0K. Diluted EPS came in at $-1.06, missed the $-0.12 consensus by $0.94.
Filings will appear here once submitted to SEC EDGAR.
Common questions about Evogene's Q2 2024 earnings report.
Evogene (EVGN) reported Q2 2024 earnings on August 22, 2024 before market open.
Evogene reported revenue of $605.0K and diluted EPS of $-1.06 for Q2 2024.
Revenue missed the consensus estimate of $800.0K by $195.0K. EPS missed the consensus estimate of $-0.12 by $0.94.